Tom Maniatis

Tom Maniatis is Professor and Chair of the Department of Biochemistry & Molecular Biophysics at the Columbia University College of Physicians and Surgeons. After postdoctoral studies at Harvard University and the Medical Research Council in Cambridge, England, Dr. Maniatis held faculty positions at Harvard University, the Cold Spring Harbor Laboratory and the California Institute of Technology before taking his present position at Columbia. Dr. Maniatis pioneered the development of gene cloning technology, and he has published extensively in the field of eukaryotic gene regulation. He co-authored the Molecular Cloning Manual, which was instrumental in the worldwide dissemination of recombinant DNA technology. Dr. Maniatis is a member of the U.S. National Academy of Sciences, and has received numerous awards for his research contributions.

Dr. Maniatis is a co-founder of Genetics Institute, where he chaired the scientific board and served on the board of directors for over 17 years. During this time the company gained FDA approval for several protein-based drugs, including recombinant human erythropoietin, Factor VIII and Factor IX, as well as bone morphogenic proteins. Dr. Maniatis was also a cofounder of ProScript Inc., which discovered the drug Velcade, currently the leading commercial product of Millennium Pharmaceuticals. More recently he co-founded Acceleron Pharma, which develops drugs for the treatment of musculoskeletal disease. He received his undergraduate education at the University of Colorado at Boulder, and his Ph.D. in molecular biology from Vanderbilt University.